The views expressed herein are those of the authors and do not necessarily reflect the views or policies of the U.S. Food and Drug Administration.
Risk Assessment for Aflatoxin: An Evaluation Based on the Multistage Model
Article first published online: 29 MAY 2006
Volume 13, Issue 6, pages 637–642, December 1993
How to Cite
Bowers, J., Brown, B., Springer, J., Tollefson, L., Lorentzen, R. and Henry, S. (1993), Risk Assessment for Aflatoxin: An Evaluation Based on the Multistage Model. Risk Analysis, 13: 637–642. doi: 10.1111/j.1539-6924.1993.tb01325.x
- Issue published online: 29 MAY 2006
- Article first published online: 29 MAY 2006
- Received December 29, 1992; revised June 14, 1993
- risk assessment;
- cancer potency;
- multistage models
Lifetime cancer potency of alfatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day)−1 for individuals negative for hepatitis B and 230 (mg/kg/day)−1 for individuals positive for hepatitis B.